Clinical Trial Update: Bioequivalence Study of Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study of Macitentan and Tadalafil 10 mg/40 mg film-coated tablets (PrOpsynvi) has completed, assessing equivalence for PAH therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Macitentan (macitentan)
• TADALAFIL (TADALAFIL)

Snippet

Sponsor: Humanis Saglık Anonim Sirketi | Conditions: PAH | Phase 1 | Status: COMPLETED